EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study

Ali Al-Janabi iD, Amelle Ra iD, Zoe Littlewood, Amy C Foulkes iD, Hamish J A Hunter, Hector Chinoy iD, Christopher A Moriarty, Kimme L Hyrich iD, Jimmy K Limdi iD, Zenas Z N Yiu iD, Christopher E M Griffiths iD, Richard B Warren iD

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljac109 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Ali Al-Janabi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manche…. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Psoriasis Association, Department of Health, National Institute for Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologic and nonbiologic immunomodulators, used to treat immune-mediated inflammatory diseases (IMIDs), could impair the immune response to COVID-19 vaccines and thus vaccine effectiveness.

Objectives

Our objective was to investigate the association between biologic and nonbiologic immunomodulators and seroconversion following the first and second dose of COVID-19 vaccines in patients with IMIDs.

Methods

Serum samples were collected following the first or second dose of the BNT162b2 or AZD1222 vaccines from patients receiving biologic and/or nonbiologic immunomodulators for one or more of psoriasis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease or systemic lupus erythematosus. Seroconversion was defined as a positive Roche Elecsys® Anti-SARS-CoV-2 S (spike protein subunit S1/receptor binding domain) immunoassay (≥ 0.8 U mL–1). Association between immunomodulator exposure and seroconversion was assessed using logistic regression, adjusting for age and sex.

Results

After excluding those with prior COVID-19, post-first vaccine dose samples from 193 participants and post-second dose samples from 312 participants were included in the analysis. Following the first vaccine dose, 17.6% (n = 34) of participants did not seroconvert. Seroconversion was reduced for those on nonbiologic [adjusted odds ratio (OR) 0.29, 95% confidence interval (CI) 0.12–0.69] or combined nonbiologic and biologic treatment (adjusted OR 0.14, 95% CI 0.045–0.45) compared with those on biologic monotherapy. Subgroup analysis demonstrated reduced odds of seroconversion in those on methotrexate (adjusted OR 0.097, 95% CI 0.19–0.49) or prednisolone treatment (adjusted OR 0.044, 95% CI 0.002–1.00) relative to tumour necrosis factor-α inhibitor monotherapy. No participants receiving rituximab (n < 5) seroconverted after the first vaccine dose. Following the second vaccine dose, 1.6% of all participants did not seroconvert. Non-seroconversion was associated with receiving rituximab (n = 3 of 4) compared with those receiving other therapies (n = 2 of 308, P < 0.001). Post hoc analyses demonstrated that non-seroconversion was associated with age [adjusted OR 0.18, 95% CI 0.037–0.93 for those aged 60 years and over (reference category age 18–39 years)], but not sex, ethnicity or vaccine type.

Conclusions

Treatment with nonbiologics, particularly methotrexate, is associated with impaired seroconversion following two BNT162b2 or AZD1222 vaccine doses, in patients with IMIDs. These findings are consistent with those of other published studies. While this could indicate reduced protection against COVID-19, the immunological parameters that correlate most closely with vaccine effectiveness need to be defined to reach this conclusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19VaccinesHumansMiddle AgedAgedAdolescentYoung AdultAdultChAdOx1 nCoV-19BNT162 VaccineCOVID-19 VaccinesRituximabImmunomodulating AgentsMethotrexateProspective StudiesImmunologic FactorsAdjuvants, ImmunologicAntibodies, Viral

Substanzen

ChAdOx1 nCoV-19BNT162 VaccineCOVID-19 VaccinesRituximabImmunomodulating AgentsMethotrexateImmunologic FactorsVaccinesAdjuvants, ImmunologicAntibodies, Viral

Autor:innen und Institutionen

  • Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK.
  • National Institute of Health Research, Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester NHS Foundation Trust, Manchester, UK.
  • Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK.
  • Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Affinity Biomarker Labs, Translation & Innovation Hub Building, Imperial College London White City Campus, London W12 0BZ, UK.
  • Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.

ORCID-Profile: Ali Al-Janabi, Amelle Ra, Amy C Foulkes, Hector Chinoy, Kimme L Hyrich, Jimmy K Limdi, Zenas Z N Yiu, Christopher E M Griffiths, Richard B Warren

Förderung

  • Psoriasis Association
  • Department of Health
  • National Institute for Health Research
  • Manchester NIHR Biomedical Research Centre
  • Medical Research Council

Zitieren

APA

Al-Janabi, A., Ra, A., Littlewood, Z., Foulkes, A. C., Hunter, H. J. A., Chinoy, H., Moriarty, C. A., Hyrich, K. L., Limdi, J. K., Yiu, Z. Z. N., Griffiths, C. E. M., & Warren, R. B. (2023). The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljac109

Vancouver

Al-Janabi A, Ra A, Littlewood Z, Foulkes AC, Hunter HJA, Chinoy H, et al. The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljac109

BibTeX
@article{AlJanabi2023,
  author = {Al-Janabi, Ali and Ra, Amelle and Littlewood, Zoe and Foulkes, Amy C and Hunter, Hamish J A and Chinoy, Hector and Moriarty, Christopher A and Hyrich, Kimme L and Limdi, Jimmy K and Yiu, Zenas Z N and Griffiths, Christopher E M and Warren, Richard B},
  title = {The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljac109}
}
Kostenlos starten →